Moberg Pharma Future Growth

Future criteria checks 2/6

Moberg Pharma is forecast to grow earnings and revenue by 85.5% and 98.2% per annum respectively while EPS is expected to grow by 82.6% per annum.

Key information

85.5%

Earnings growth rate

82.6%

EPS growth rate

Pharmaceuticals earnings growth	69.6%
Revenue growth rate	98.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Aug 2024

Recent future growth updates

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Earnings and Revenue Growth Forecasts

OM:MOB - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	101	7	8	21	1
12/31/2025	44	-7	-5	19	1
12/31/2024	9	-22	-84	-25	1
6/30/2024	5	-23	-134	-33	N/A
3/31/2024	1	-23	-139	-31	N/A
12/31/2023	N/A	-21	-157	-33	N/A
9/30/2023	N/A	-18	-133	-29	N/A
6/30/2023	0	-16	-105	-21	N/A
3/31/2023	0	-16	-96	-16	N/A
12/31/2022	0	-16	-85	-17	N/A
9/30/2022	0	-17	-75	-14	N/A
6/30/2022	N/A	-16	-70	-12	N/A
3/31/2022	N/A	-16	-56	-7	N/A
12/31/2021	N/A	-16	-47	-15	N/A
9/30/2021	34	8	-44	-9	N/A
6/30/2021	34	7	-46	-12	N/A
3/31/2021	34	5	-58	-16	N/A
12/31/2020	34	7	-52	-10	N/A
6/30/2020	50	20	-47	4	N/A
6/30/2019	31	-8	-140	-76	N/A
3/31/2019	455	31	15	88	N/A
12/31/2018	5	-28	-10	74	N/A
9/30/2018	341	9	-2	87	N/A
6/30/2018	340	19	85	109	N/A
3/31/2018	334	6	N/A	68	N/A
12/31/2017	439	11	N/A	54	N/A
9/30/2017	438	-1	N/A	30	N/A
6/30/2017	434	0	N/A	-44	N/A
3/31/2017	369	35	N/A	-17	N/A
12/31/2016	334	33	N/A	-18	N/A
9/30/2016	299	36	N/A	-21	N/A
6/30/2016	261	32	N/A	12	N/A
3/31/2016	282	9	N/A	32	N/A
12/31/2015	286	26	N/A	31	N/A
9/30/2015	276	25	N/A	34	N/A
6/30/2015	260	20	N/A	30	N/A
3/31/2015	226	19	N/A	14	N/A
12/31/2014	200	12	N/A	16	N/A
9/30/2014	193	12	N/A	11	N/A
6/30/2014	179	4	N/A	1	N/A
3/31/2014	167	-5	N/A	-6	N/A
12/31/2013	157	-11	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOB's revenue (98.2% per year) is forecast to grow faster than the Swedish market (-0.02% per year).

High Growth Revenue: MOB's revenue (98.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MOB's Return on Equity is forecast to be high in 3 years time

Moberg Pharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 26% to kr29.00

Recent updates

Moberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025

Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

New minor risk - Market cap size

Now 64% undervalued after recent price drop

Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus

Price target increased by 26% to kr29.00

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Now 22% undervalued

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure

New major risk - Share price stability

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Moberg Pharma Announces Leadership Changes

Moberg Pharma AB (publ) Appoints Nomination Committee

Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America

New major risk - Shareholder dilution

Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden

Moberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults

Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union

New major risk - Market cap size

Moberg Pharma AB (Publ) Recommends for Approval in EU

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Less than half of directors are independent

Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team

Moberg Pharma AB (publ), Annual General Meeting, May 16, 2023

Moberg Pharma AB (publ) Approves Board Appointments

Peter Wolpert and Fredrik Granström Step-Down from the Board

Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study

Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election

The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application

Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis

Moberg Pharma AB's Paid Subscription Units to Be Delisted

New 90-day low: kr6.40

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

New 90-day low: kr9.05

Market pulls back on stock over the past week

Moberg Pharma AB (publ) to Report Q1, 2021 Results on May 11, 2021

Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021

Moberg Pharma AB (Publ) Appoints Nomination Committee

Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021

New 90-day low: kr11.30

New 90-day low: kr13.52

Caret Pharma LLC entered into an agreement to acquire the assets of Fiber Choice® from Moberg Pharma AB (publ) (OM:MOB) for $6.7 million.

Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index

New 90-day low - kr14.01

Earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies